Search
Oral Presentation
Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
Hollebecque A, Goyal L, Meric-Bernstam F, et al.
Oral Presentation
Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
Satoh T, Barthélémy P, Nogova L, et al.
Oral Presentation
Health‑related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
Prager G, Taieb J, Fakih M, et al.